Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.35 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.33 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17132557 | 0.87 | IRAK4 (0.34) | IRAK4HTR2AHTR2C | |
| SCHEMBL6569097 | 0.84 | SMPD3 (0.36) | UGT2B7HTR2AHTR2C | |
| SCHEMBL31003311 | 0.75 | NR3C1 (0.33) | CYP11B1CYP11B2UGT2B7 | |
| SCHEMBL15715207 | 0.74 | EPHB3 (0.42) | IRAK4EPHB3 | |
| SCHEMBL31003279 | 0.73 | IRAK4 (0.33) | IRAK4UGT2B7 | |
| SCHEMBL26596835 | 0.71 | FYN (0.32) | — | |
| SCHEMBL31003361 | 0.71 | NPC1 (0.44) | CYP11B1CYP11B2IRAK4EPHB3 | |
| SCHEMBL29026988 | 0.70 | PIK3CA (0.40) | EPHB3 | |
| SCHEMBL24656165 | 0.70 | KCNH2 (0.36) | CYP11B1CYP11B2IRAK4 | |
| SCHEMBL21819027 | 0.69 | ADH5 (0.38) | IRAK4EPHB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658656-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEONE MEDICINES I GMBH (CH) | 2025-11-13 | — | — | US | disclosed |
| WO-2024160276-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEIGENE, LTD. (KY) | 2024-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | DGKG, DGKA, DGKK | CYP11B1 3959/4885CYP11B2 4207/4885IRAK4 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.